Published by Wanda Rich
Posted on September 6, 2021
Global Bispecific Antibody Market is valued atUSD 489.7 Million in 2020and expected to reachUSD 810.4 Million by 2027|CAGR of 6.5%
Increasing research and development for novel bispecific antibodies is one of the major factors driving the Global Bispecific Antibodies Market.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Request Premium Sample of the Report: https://brandessenceresearch.com/requestSample/PostId/1129
Bispecific antibody is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Most of the bispecific antibodies are being developed for the treatment of multiple cancers followed by infectious disease, CNS disorders, inflammatory and autoimmune disorders. The benefits of bispecific antibodies over monoclonal therapeutics are due to their higher binding avidity to targets, which can interact with more than one surface antigen and boosted cytotoxic effects. It is because of the direct recruitment of effector cells to the site of the disease or in tumorigenic conditions. Bispecific antibodies may be used to improve clinical efficacy by targeting two disease mechanisms for the treatment of complex human diseases in a single agent. Bispecific antibodies also hold promise for certain therapeutic applications difficult to achieve by single-targeting monospecific antibodies, such as immune cell retargeting, site-specific targeting, enabling therapeutics to cross the blood- brain barrier, and unique receptor modulation.
Global Bispecific Antibody market is segmented on the basis of type, application and regional & country level. Based upon type, bispecific antibody market is classified into catumaxomab (removab), blinatumomab, duligotumab and SAR 156597. Based upon application, the market is classified into BSMAB for diagnosis of infectious diseases, diagnosis of bacterial infections, diagnosis of viral infections, BSMAB for cancer diagnostic, BsAbs blocking signaling pathways, BSABS targeting tumor angiogenesis, specific delivery of effector compounds to targets and bispecific antibodies and gene therapy.
The regions covered in this Global bispecific antibody market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level market of bispecific antibody is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Global Bispecific Antibody market Report covers prominent players are like,
Aspen Holdings
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Company
Limited
GlaxoSmithKline plc.
Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
Pfizer, Inc
Portola Pharmaceuticals, Inc.
Sanofi S.A.
Others
Increasing Research and Development for Novel Bispecific Antibodies is one of the Major Factors Driving the Global Bispecific Antibodies Market.
Increasing research and development for novel bispecific antibodies is expected to drive the growth of bispecific antibodies market. Bispecific antibodies can be manufactured in several structural formats, and current applications have been explored for cancer immunotherapy and drug delivery. According to American Association for Cancer Research, Approximately 15% of all newly diagnosed cancers are lung cancer, which are the most common cancer and the leading cause of cancer death worldwide. In the 2017 World Health Statistics Report released by the WHO, cancer ranks the second most common cause of death following cardiovascular diseases around the world. One out of every ten deaths is caused by cancer and there is an apparent rising trend in the world. Tumor-specific monoclonal antibodies (mAbs) have revolutionized the treatment of cancer. The combination of tumor-specific mAbs with traditional chemotherapy has greatly extended the patients survival time and 5-year survival rate. Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals may hamper the growth of this market. In spite of that, structural diversity among the antibodies are opening a wide Plethora for the novel bispecific antibody agents, and thus providing a great opportunity for bispecific antibody market in the future.
North America is Expected to Dominate the Global Bispecific Antibody Market
North America is expected to dominate the global bispecific antibody market due to growing incidences of cancer such as lung cancer, cervical cancer, breast cancer, and prostate cancer. According to national cancer institute, in 2018, an estimated 1,735,350 new cases of cancer will be diagnosed in the United States and 609,640 people will die from the disease. Europe is considered as an emerging market in bispecific antibodies treatment due to growing market penetration in this region. Advances in biotechnology leading to improved antibody production and recombination techniques have fueled the development of antibodies and myriad antibody constructs. Also Asia Pacific market growth is attributed to the presence of untapped opportunities due to extensive improvement in the healthcare infrastructure in this region.
Key Benefits
Global market report covers in depth historical and forecast analysis.
Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
Global market report helps to identify opportunities in market place.
Global market report covers extensive analysis of emerging trends and competitive landscape.
By Type:Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597
By Applications:BsMAb for Cancer Diagnostic, BsMAb for Diagnosis of Bacterial & Infectious Diseases, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis, Specific Delivery of Effector Compounds to Targets, Bispecific Antibodies and Gene Therapy
Regional & Country Analysis
North America
Europe
Asia Pacific
Latin America
Get Full Report: @ https://brandessenceresearch.com/healthcare/bispecific-antibody-market-size
About us: Brandessence Market Research and Consulting Pvt. Ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us atsales@brandessenceresearch.com
Global Bispecific Antibody Market is valued atUSD 489.7 Million in 2020and expected to reachUSD 810.4 Million by 2027|CAGR of 6.5%
Increasing research and development for novel bispecific antibodies is one of the major factors driving the Global Bispecific Antibodies Market.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Request Premium Sample of the Report: https://brandessenceresearch.com/requestSample/PostId/1129
Bispecific antibody is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Most of the bispecific antibodies are being developed for the treatment of multiple cancers followed by infectious disease, CNS disorders, inflammatory and autoimmune disorders. The benefits of bispecific antibodies over monoclonal therapeutics are due to their higher binding avidity to targets, which can interact with more than one surface antigen and boosted cytotoxic effects. It is because of the direct recruitment of effector cells to the site of the disease or in tumorigenic conditions. Bispecific antibodies may be used to improve clinical efficacy by targeting two disease mechanisms for the treatment of complex human diseases in a single agent. Bispecific antibodies also hold promise for certain therapeutic applications difficult to achieve by single-targeting monospecific antibodies, such as immune cell retargeting, site-specific targeting, enabling therapeutics to cross the blood- brain barrier, and unique receptor modulation.
Global Bispecific Antibody market is segmented on the basis of type, application and regional & country level. Based upon type, bispecific antibody market is classified into catumaxomab (removab), blinatumomab, duligotumab and SAR 156597. Based upon application, the market is classified into BSMAB for diagnosis of infectious diseases, diagnosis of bacterial infections, diagnosis of viral infections, BSMAB for cancer diagnostic, BsAbs blocking signaling pathways, BSABS targeting tumor angiogenesis, specific delivery of effector compounds to targets and bispecific antibodies and gene therapy.
The regions covered in this Global bispecific antibody market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level market of bispecific antibody is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Global Bispecific Antibody market Report covers prominent players are like,
Aspen Holdings
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Company
Limited
GlaxoSmithKline plc.
Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
Pfizer, Inc
Portola Pharmaceuticals, Inc.
Sanofi S.A.
Others
Increasing Research and Development for Novel Bispecific Antibodies is one of the Major Factors Driving the Global Bispecific Antibodies Market.
Increasing research and development for novel bispecific antibodies is expected to drive the growth of bispecific antibodies market. Bispecific antibodies can be manufactured in several structural formats, and current applications have been explored for cancer immunotherapy and drug delivery. According to American Association for Cancer Research, Approximately 15% of all newly diagnosed cancers are lung cancer, which are the most common cancer and the leading cause of cancer death worldwide. In the 2017 World Health Statistics Report released by the WHO, cancer ranks the second most common cause of death following cardiovascular diseases around the world. One out of every ten deaths is caused by cancer and there is an apparent rising trend in the world. Tumor-specific monoclonal antibodies (mAbs) have revolutionized the treatment of cancer. The combination of tumor-specific mAbs with traditional chemotherapy has greatly extended the patients survival time and 5-year survival rate. Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals may hamper the growth of this market. In spite of that, structural diversity among the antibodies are opening a wide Plethora for the novel bispecific antibody agents, and thus providing a great opportunity for bispecific antibody market in the future.
North America is Expected to Dominate the Global Bispecific Antibody Market
North America is expected to dominate the global bispecific antibody market due to growing incidences of cancer such as lung cancer, cervical cancer, breast cancer, and prostate cancer. According to national cancer institute, in 2018, an estimated 1,735,350 new cases of cancer will be diagnosed in the United States and 609,640 people will die from the disease. Europe is considered as an emerging market in bispecific antibodies treatment due to growing market penetration in this region. Advances in biotechnology leading to improved antibody production and recombination techniques have fueled the development of antibodies and myriad antibody constructs. Also Asia Pacific market growth is attributed to the presence of untapped opportunities due to extensive improvement in the healthcare infrastructure in this region.
Key Benefits
Global market report covers in depth historical and forecast analysis.
Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
Global market report helps to identify opportunities in market place.
Global market report covers extensive analysis of emerging trends and competitive landscape.
By Type:Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597
By Applications:BsMAb for Cancer Diagnostic, BsMAb for Diagnosis of Bacterial & Infectious Diseases, BsAbs Blocking Signaling Pathways, BsAbs Targeting Tumor Angiogenesis, Specific Delivery of Effector Compounds to Targets, Bispecific Antibodies and Gene Therapy
Regional & Country Analysis
North America
Europe
Asia Pacific
Latin America
Get Full Report: @ https://brandessenceresearch.com/healthcare/bispecific-antibody-market-size
About us: Brandessence Market Research and Consulting Pvt. Ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals, and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations, and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us atsales@brandessenceresearch.com
Explore more articles in the Research Reports category
